Densmore Pharmaceutical Laboratory Competitors and Similar CompaniesClear all

Densmore Pharmaceutical Laboratory's competitors and similar companies include ERELA, Laboratorios Garden House, Moderna and Regeneron Pharmaceuticals.

	Densmore Pharmaceutical Laboratory Densmore Pharmaceutical Laboratory is a company focused on research and drug development in the fields of ophthalmology and gynecology.	ERELA ERELA is a manufacturer of pharmaceutical products.	Laboratorios Garden House Laboratorios Garden House is a pharmaceutical laboratory that manufactures medicines.	Moderna Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.	Regeneron Pharmaceuticals Regeneron Pharmaceuticals is a biopharmaceutical company that develops, manufactures, and markets medicines.
Founding Date	Founding Date 1946	Founding Date 1965	Founding Date N/A	Founding Date 2010	Founding Date 1988
Type	Type Subsidiary	Type Private	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech clinical research drug development pharma supplements	Tags Healthcare clinical research drug development pharma supplements	Tags Healthcare clinical research drug development pharma supplements	Tags Healthcare biotech clinical research drug development pharma	Tags Healthcare biotech clinical research drug development pharma
Locations	Locations Monaco, MC HQ	Locations ID HQ	Locations San Bernardo, CL HQ	Locations Cambridge, US HQ Melbourne, AU Paris, FR München, DE Tokyo, JP Seoul, KR Warszawa, PL see more	Locations Tarrytown, US HQ Mississauga, CA Courbevoie, FR München, DE Bengaluru, IN Dublin, IE Limerick, IE see more
Employees	Employees 509% increase	Employees N/A	Employees 1881% increase	Employees 5,8004% increase	Employees 15,1068% increase
Valuation ($)	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 21.2 b	Valuation ($) 102.2 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $1.9b (FY, 2025)	Revenue (est.) $14.3b (FY, 2025)
Net income	Net income N/A	Net income N/A	Net income N/A	Net income ($2.8b) (FY, 2025)	Net income $4.5b (FY, 2025)
Operating ⚠
Patents (US)	Patents (US) N/A	Patents (US) N/A	Patents (US) N/A	Patents (US) 170 (FY, 2021)	Patents (US) 31 (FY, 2020)
Funding
Total funding raised	Total funding raised N/A	Total funding raised N/A	Total funding raised N/A	Total funding raised $ 1.8b	Total funding raised $ 53.9m